page antibody Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9)
|
|
- Violet Todd
- 8 years ago
- Views:
Transcription
1 New IHC Antibodies
2 2 Table of Contents page antibody Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9) Caveolin-1 (2297) CD13 (SP187) CD16 (SP175) CD123 (6H6) Cytokeratin (CAM 5.2) Cytokeratin 10 (EP97) * EGFR (SP84) EZH2 (11) FOXA1 (2F83) GATA3 (L50-823) GLUT3 (polyclonal) Glutamine Synthetase (GS-6) Heat Shock Protein 27 (G3.1) Langerin (12D6) MUC4 (8G7) MyoD1 (EP212) * Napsin A (MRQ-60) Nestin (10C2) Olig2 (211F1.1) Parvalbumin (2E11) S100A1 (EP184) * SALL4 (6E3) SOX-10 (polyclonal) Stathmin (SP49) Thyroid Peroxidase (EP159) * TIA-1 (EP243) * TLE1 (1F5) (ASR): Adenovirus (20/11 & 2/6) (ASR): Estrogen Receptor (EP1) * (ASR): Herpes Simplex Virus I (10A3) (ASR): Treponema pallidum (polyclonal)
3 New IHC Antibodies 1 Adipophilin (polyclonal) Adipophilin is useful in the identification of intracytoplasmic lipids in sebaceous neoplasms. Anti-adipophilin has high sensitivity and specificity for labeling sebaceous neoplasms, which helps distinguish them from basal cell carcinomas and squamous cell carcinomas. It is also helpful in the identification of more challenging cases of sebaceous carcinomas like small periocular biopsy specimens. 0.1 ml, concentrate A ml, concentrate A ml, concentrate A ml, predilute A ml, predilute A-18 5 Positive control slides S ALDH1A1 (44) ALDH1A1 aids in the identification of solitary fibrous tumors. It is primarily expressed in normal tissues of the epithelium of brain, eye, kidney, testis, and hematopoietic stem cells. ALDH1A1, when incorporated into an immunohistochemical panel, can aid in the differentiation between solitary fibrous tumor (SFT)/hemangiopericytoma (HPC) and meningioma, or synovial sarcoma. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S c-myc (EP121) * Anti-c-Myc (EP121) * is a highly sensitive diagnostic marker for chromosome 8 translocations indicative of Burkitt lymphoma. This marker is often used in a panel with CD20, CD10, BCL6, BCL2, and Ki-67 for the differential diagnosis of highly aggressive Burkitt lymphoma. c-myc is also overexpressed in some breast carcinomas and prostate carcinomas. Unlike many other established clones of c-myc, which have a history of compatibility limitations with hematolymphoid neoplasms, Cell Marque s c-myc (EP121) * can be used as an aid on prostate, breast, and lymphomas! 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S Cadherin-17 (SP183) Cadherin-17 is expressed in many adenocarcinomas including colorectal, pancreatic, and gastric. Cadherin-17 is most commonly used in colorectal adenocarcinomas due to its diffuse and strong staining. In other adenocarcinomas, such as stomach, pancreas, and bile duct, cadherin-17 can be visualized as focal or scattered. Cadherin-17 can be complementary to E-Cadherin as they are both expressed in the intestinal mucosa. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S Cathepsin K (3F9) Cathepsin K aids in the identification of translocation renal cell carcinoma. In recent literature, it has been reported that cathepsin K is highly specific for translocation RCC and can help distinguish it from different types of RCC and other carcinomas. It can also be expressed in alveolar soft part sarcomas. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S
4 2 Caveolin-1 (2297) Caveolin-1 is useful in differentiating epithelioid mesothelioma (+) from lung adenocarcinoma ( ). This marker is a valuable addition to lung panels that include Napsin A, TTF-1, CEA, and Ber-EP4. Caveolin-1 is comparable to, and in some cases superior to other established markers for mesothelioma such as podoplanin, calretinin, HBME-1, and WT ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S CD13 (SP187) CD13 s primary application is for acute myeloid leukemia (AML). Hematopathologists will find this antibody helpful in differentiating subtypes of AML. CD13 is expressed in myelomonocyctic cells in the late stage while CD33 stains the myeloblastic cells in the earlier stages of AML. These markers can be run together to help determine what stage of AML a patient is in. CD13 can also be used to differentiate myeloid sarcoma from mimicking carcinomas. It can be used in a panel with CD34, CD43, CD33, and MPO to help differentiate myeloid sarcoma in the late stage. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S CD16 (SP175) CD16 is expressed in NK-cell lymphoma and stains specifically for NK leukemia in bone marrow. Anti-CD16 can be used in a panel with CD56, because CD16 can stain NK leukemia but does not stain NK/T-cell lymphoma, nasal type, which CD56 is known for. This antibody is also used in differentiating NK leukemia from other types of leukemia such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S CD123 (6H6) CD123 aids in the identification of blastic plasmacytoid dendritic cell neoplasm (BPDCN). CD123 is useful in differentiating BPDCN from myeloid sarcoma and large aggressive B cell lymphoma. When used in a panel with CD4, CD56, and TCL-1, CD123 can help distinguish between myeloid leukemia cutis and BPDCN. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S Cytokeratin (CAM 5.2) Cytokeratin (CAM 5.2) is the most widely recognized low molecular weight keratin. CAM 5.2 is a marker that can be used in the identification of hepatocellular neoplasms, which are negative for Cytokeratin Cocktail (AE1/AE3), as well as for lymph node metastases of breast cancer and lung cancer. It can also be used to stain simple epithelia. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M ml, predilute M-90 5 Positive control slides S
5 New IHC Antibodies 3 Cytokeratin 10 (EP97) * Cytokeratin 10 is used in the identification of squamous cell carcinomas. It is present in all suprabasal epithelial cells (stratified epithelium). Squamous cell carcinoma can arise from any type of stratified epithelium. Cytokeratin 10 can then help differentiate squamous cell carcinomas from non-squamous cell carcinomas. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S EGFR (SP84) EGFR, also known as Epidermal Growth Factor Receptor, ErbB-1, and Her1, is used in the diagnosis of carcinomas. In a study conducted at Cell Marque and presented at USCAP 2014, EGFR was positive in 90% of triple negative breast carcinomas. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S EZH2 (11) EZH2 is a marker used in the differential diagnosis of carcinomas. EZH2 is also helpful in differentiating follicular lymphoma (+) and mantle cell lymphoma (+) from marginal zone lymphoma ( ) and MALT lymphoma ( ). 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S FOXA1 (2F83) FOXA1 assists in the sub-classification of breast carcinomas. FOXA1 is a marker that can also be useful in the identification of luminal A subtype when used with ER, PR, and Her2/Neu. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S GATA3 (L50-823) GATA3 expression is primarily seen in breast carcinoma. GATA3 is expressed in ALL lobular breast carcinomas and in a high percentage of invasive ductal carcinomas. GATA3 is negative in lung and thyroid carcinomas. It has been reported in literature that GATA3 expression is correlated with the status of ER, PR, and Her2/Neu in breast carcinoma. Another important application for GATA3 is in the identification of urothelial carcinomas. It is especially expressive in invasive and high-grade tumors, and is negative in prostate and renal cell carcinomas. Unlike other markers that have similar applications, GATA3 has a nuclear visualization. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S
6 4 GLUT3 (polyclonal) GLUT3 is valuable in the identification of germ cell tumors and differentiating them from non-germ cell tumors and neoplasms. GLUT3 is commonly used in panels with SALL4 and Oct-4 (also known as Oct ¾). 0.1 ml, concentrate A ml, concentrate A ml, concentrate A ml, predilute A ml, predilute A-18 5 Positive control slides S Glutamine Synthetase (GS-6) Glutamine synthetase is a key marker in the identification of liver neoplasms, especially hepatocellular carcinoma. In HCC, glutamine synthetase is expressed strongly and diffusely in malignant hepatocytes. It can be used in a panel with glypican-3 and HSP70 to help distinguish between dysplastic and early malignant hepatocellular nodules appearing in cirrhosis. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S Heat Shock Protein 27 (G3.1) Heat shock protein 27 (HSP27) is useful in the identification of high-grade dysplasia and cervical squamous cell carcinoma. A well-known cervical marker, p16, stains both high and low-grade dysplasia. It has been reported that HSP27 is expressed in a higher percentage of cervical squamous cell carcinomas than p16 (Tozawa-Ono A, et al. Human Cell 2012; 25:24 28). HSP27 is recommended as a complementary antibody to p16 for routine cervical dysplasia and cervical cancer testing. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S Langerin (12D6) Langerin can aid in the diagnosis of Langerhans cell histiocytosis due to its high sensitivity and specificity for Langerhans cells. Evaluation of Langerin expression is valuable in circumstances where a diagnosis of Langerhans cell histiocytosis is suspected, but cannot be confirmed due to the lack of CD1a immunoreactivity. Langerin can also be utilized to help differentiate between Langerhans cell histiocytosis and other histiocytic proliferations. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S MUC4 (8G7) Anti-MUC4 is the most valuable marker available for diagnosing low-grade fibromyxoid sarcoma. MUC4 immunohistochemistry is also a valuable tool for differentiating malignant pancreatic lesions (PDA and IPMN, which are both MUC4 positive) from benign pancreas (which is MUC4 negative). 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S
7 New IHC Antibodies 5 MyoD1 (EP212) * MyoD1 is highly sensitive and specific for rhabdomyosarcoma. It has a high sensitivity for both alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma. Anti-MyoD1 is often used with anti-myogenin due to their varying specificity and sensitivity for rhabdomyosarcoma. Unlike other established clones of MyoD1, which have a history of compatibility limitations with automation and detections, Cell Marque s MyoD1 (EP212) * is compatible with multiple automated platforms! 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S Napsin A (MRQ-60) Napsin A is commonly used to identify adenocarcinoma of the lung. It can be used in a panel with TTF 1, cytokeratin 5/14, and SOX 2 to differentiate lung adenocarcinoma from lung squamous cell carcinoma, an essential distinction to make when determining eligibility for various therapies. Napsin A is highly sensitive for lung adenocarcinoma including poorly differentiated lung adenocarcinoma, which can be missed by other markers. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-98 5 Positive control slides S Nestin (10C2) Nestin expression is correlated with advanced stages of melanoma. Like Cell Marque s SOX-10 (polyclonal), nestin exhibits positive staining in desmoplastic melanoma. Nestin is also considered an important marker for HMB-45 negative nodular melanoma as well as triple negative breast carcinoma of the basal phenotype. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S Olig2 (211F1.1) Olig2 is involved in oligodendroglial specifications. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Double staining with Olig2 and GFAP can be used in the characterization of astrocytomas, oligoastrocytomas and oligodendrogliomas. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S Parvalbumin (2E11) Parvalbumin expression is correlated with chromophobe renal cell carcinoma. This antibody has been requested as a possible replacement for the colloidal iron stain on kidneys. Parvalbumin helps distinguish chromophobe renal cell carcinoma from clear cell RCC and papillary RCC. Oncocytomas show reactivity for parvalbumin, as well. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S
8 6 S100A1 (EP184) * S100A1 is used in identifying renal oncocytoma. S100A1 differentiates renal oncocytoma from chromophobe renal cell carcinoma of the kidney. Combined with other IHC markers such as parvalbumin, CD117, Ksp-cadherin, and vimentin, S100A1 can be very useful in subtyping renal cell carcinoma. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S SALL4 (6E3) SALL4 (6E3) is a valuable pan-germ cell tumor marker. It is seen to demonstrate high sensitivity for tumor cells in intratubular germ cell neoplasia, seminomas/ dysgerminomas, embroyonal carcinomas, and yolk sac tumors. Anti-SALL4 also stains teratomas and mononucleated trophoblastic cells in choriocarcinomas. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S SOX-10 (polyclonal) Anti-SOX-10 is a sensitive marker of melanoma, including conventional, spindled, and desmoplastic subtypes. Its strong nuclear staining provides a cleaner signal than other antibodies like anti-s-100. The established pan melanoma markers, such as anti-hmb-45 and anti-mart-1/melan A, are known to have low expression in desmoplastic melanoma, which is one of SOX-10 s primary advantages. Anti-SOX-10 will not stain dendritic cells, macrophages, or fibroblasts when metastasis occurs. 0.1 ml, concentrate A ml, concentrate A ml, concentrate A ml, predilute A ml, predilute A-78 5 Positive control slides S Stathmin (SP49) Stathmin can be utilized to distinguish high-grade dysplasia (CIN II and CIN III) from low-grade dysplasia (CIN I). This distinction is very important as the current standard, p16, is unable to differentiate the different types of CIN since it stains all dysplasia equally. Stathmin is best used in a panel with p16, Ki-67, and Cytokeratin 17 for dysplasia and atypical immature metaplasia (AIM). 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S Thyroid Peroxidase (EP159) * Thyroid Peroxidase (TPO) is a useful marker for identifying thyroid carcinoma. When used in a panel with HBME-1, galectin-3 and cytokeratin 19, TPO can help with the identification of thyroid carcinoma of the papillary and follicular types. TPO is also useful in differentiating metastatic thyroid carcinoma from other carcinomas, especially lung adenocarcinoma. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S
9 New IHC Antibodies 7 TIA-1 (EP243) * TIA-1 aids in the diagnosis of NK/T-cell lymphomas, hepatosplenic T-cell lymphomas, and anaplastic large cell lymphomas (ALCL). TIA-1 is often used with other cytotoxic granular markers, such as granzyme B and perforin, in T-cell lymphoma panels. 0.1 ml, concentrate R ml, concentrate R ml, concentrate R ml, predilute R ml, predilute R-18 5 Positive control slides S TLE1 (1F5) TLE1 is a marker that is highly sensitive for synovial sarcoma, a soft tissue sarcoma, which has historically been difficult to diagnose. It may be used in a panel to distinguish synovial sarcoma from other soft tissue malignancies. TLE1 has been shown to be more specific and sensitive for synovial sarcoma than established markers including BCL2, EMA, and cytokeratin cocktail. 0.1 ml, concentrate M ml, concentrate M ml, concentrate M ml, predilute M ml, predilute M-18 5 Positive control slides S
10 8 Analyte Specific Reagents (ASR) Adenovirus (20/11 & 2/6) Estrogen Receptor (EP1) * 0.1 ml, concentrate...212m-14 (ASR) 0.5 ml, concentrate...212m-15 (ASR) 1.0 ml, concentrate...212m-16 (ASR) 1.0 ml, predilute...212m-17 (ASR) 7.0 ml, predilute...212m-18 (ASR) 0.1 ml, concentrate...249r-24 (ASR) 0.5 ml, concentrate...249r-25 (ASR) 1.0 ml, concentrate...249r-26 (ASR) 1.0 ml, predilute...249r-27 (ASR) 7.0 ml, predilute...249r-28 (ASR) Herpes Simplex Virus I (10A3) Treponema pallidum (polyclonal) 0.1 ml, concentrate...361m-14 (ASR) 0.5 ml, concentrate...361m-15 (ASR) 1.0 ml, concentrate...361m-16 (ASR) 1.0 ml, predilute...361m-17 (ASR) 7.0 ml, predilute...361m-18 (ASR) 0.1 ml, concentrate...397a-14 (ASR) 0.5 ml, concentrate...397a-15 (ASR) 1.0 ml, concentrate...397a-16 (ASR) 1.0 ml, predilute...397a-17 (ASR) 7.0 ml, predilute...397a-18 (ASR) Powered by Technology * Rabbit Monoclonals Produced Using Technology from Epitomics, Inc. Under Patent No. 5,675,063 Rev. 0.3
11 25 25 ANTIBODIES ML THE LIST New Convenient Value Size! The number of immunohistochemistry stains has increased tremendously over the last few years. Customers have requested larger sizes, and now Cell Marque is pleased to offer 25 antibodies in a 25 ml size to meet your growing laboratory needs. Actin, Smooth Muscle (1A4)...#202M-90 BCL2 (124)...#226M-90 CD3 (polyclonal)...#103a-70 CD20 (L26)...#120M-80 CD45 (LCA) (2B11 & PD7/26)...#145M-90 Chromogranin A (LK2H10)...#238M-90 Cytokeratin (34betaE12)...#334M-80 Cytokeratin (CAM 5.2)...#452M-90 Cytokeratin 5 & 6 (D5 & 16B4)...#356M-10 Cytokeratin 7 (OV-TL 12/30)...#307M-90 Cytokeratin 8 & 18 (B22.1 & B23.1)...#818M-90 Cytokeratin 20 (Ks20.8)...#320M-10 Cytokeratin Cocktail (AE1 & AE3)...#313M-10 EMA (E29)...#247M-90 Ep-CAM (MOC-31)...#248M-10 Helicobacter pylori (polyclonal)...#215a-70 Kappa (L1C1)...#274M-90 Lambda (Lamb14)...#277M-90 MART-1 (Melan A) (M2-7C10)...#281M-90 Melanoma Cocktail (HMB-45 + A103 + T311)..#904H-00 P504s (13H4)...#504R-10 (ASR) S-100 (4C4.9)...#330M-10 Synaptophysin (polyclonal)...#336a-70 TTF-1 (8G7G3/1)...#343M-90 Vimentin (V9)...#347M-10 Are you ready to start saving? TOP 5 Want to Save Time? How about money? The availability of 25 ml sizes of select antibodies has become a huge hit! Laboratories all over the country are taking advantage of the savings. Here is a list of our top five best-selling 25 ml antibodies. Cytokeratin 7 (OV-TL 12/30)...#307M-90 Benefits: Resist rising laboratory costs with an economical bulk size Reduce shipping costs, fuel surcharges and other hidden fees Cut validation efforts with a larger volume, single-lot product Minimize your carbon footprint with fewer deliveries Extend shelf-life with 3 year expiration dates Cytokeratin 20 (Ks20.8)...#320M-10 Cytokeratin Cocktail (AE1 & AE3)...#313M-10 Helicobacter pylori (polyclonal)...#215a-70 P504s (13H4)...#504R-10 (ASR)
12 From Passion to Product to Patient. Toll-Free: Direct:
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationOvarian tumors Ancillary methods
Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of
More informationHow To Test For Cancer With A Blood Test
Histolab Products AB Eva Alströmer Jonas Falgén Helsingborg 7-8/10 2010 Table 1 Formalin Fixation Times and Estrogen Receptor Staining With 25 Minutes Antigen Retrieval Pretreatment Formalin Q-Score Difference
More informationHKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
More informationImmunohistochemistry of soft tissue tumors
Immunohistochemistry of soft tissue tumors Immunohistochemistry Major advances : antigen retrieval techniques (HIER) sensitive detection systems numerous antibodies of good quality Standardization : automated
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationAcadémie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
More informationIndex. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, 272-275 5-HT, see Serotonin
A Acantholytic squamous cell carcinoma vs epithelioid angiosarcoma, 56-57 Acinic cell carcinoma of pancreas, 76-77 vs ductal adenocarcinoma, 74-75 vs islet cell tumor, 78-81 Adenomatoid tumor vs hemangioma,
More informationMODERN IMMUNOHISTOCHEMISTRY
MODERN IMMUNOHISTOCHEMISTRY Cambridge Illustrated Surgical Pathology Peiguo G. Chu City of Hope National Medical Center, Duarte, California Lawrence M. Weiss City of Hope National Medical Center, Duarte,
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationLessons from a consultation practice
Pitfalls in the Application of Immunohistochemistry in Diagnostic Pathology Lessons from a consultation practice Kevin O. Leslie, MD Professor and Consultant Mayo Clinic Arizona Scottsdale, Arizona Presenter
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationEfficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach
Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationExcellent FFPE. Staining
Outstanding Markers Excellent FFPE Staining Superior Staining Quality High Titer Best Price O P T I S TA I N Anti-PD-1 (clone NAT105) - a marker for follicular helper T cells (T FH ) and T-cell lymphomas
More informationA23: Oncologic Disease- Tumor Markers
A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationContents. 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1. 2. Head, Neck, Orbit and Salivary Glands... 12
Contents 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1 Complications 1 Fine Needle Aspiration Technique 1 Evaluation of FNAC Smear 4 Cell Morphology 4 Nucleus 4 Cytoplasm 6 Background
More informationEffusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
More informationIntroduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationPathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationImmunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin
Immunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin Rodney T. Miller, M.D. Director of Immunohistochemistry ProPath Laboratory 1355 River Bend Drive Dallas, TX 75247-4915
More informationImmunohistochemical classification of the unknown primary tumour
Immunohistochemical classification of the unknown primary tumour NordiQC Workshop 2014 Prof. Mogens Vyberg Institute of Pathology Aalborg, Denmark PART 2 Secondary panels for carcinoma identification/subclassification
More informationDisclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of
More informationCatalogNo Product Name Size
SIG-3250-1000 α-1-antichymotrypsin Polyclonal Antibody, Purified (SIGNET) SIG-3250-16 α-1-antichymotrypsin Polyclonal Antibody, Purified (SIGNET) L1 6mL SIG-3250-26 α-1-antichymotrypsin Polyclonal Antibody,
More informationCase based applications part III
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationHow To Test For Cancer
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic
More informationImmunohistochemistry on cytology specimens from pleural and peritoneal fluid
Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have
More informationNotice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
More informationCytokeratins and generel epithelial markers in tumour classification
Cytokeratins and generel epithelial markers in tumour classification 42, liver adenocarcinoma of unknown primary Colonrectum? Pancreas/biliary tract? Stomach? Lung? Ovary/endometrium? Mogens Vyberg, NordiQC
More informationThe term undifferentiated tumor has been used in reference
Undifferentiated Tumor True Identity by Immunohistochemistry Armita Bahrami, MD; Luan D. Truong, MD; Jae Y. Ro, MD, PhD Context. Undifferentiated tumor refers to a heterogeneous group of neoplasms with
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationTUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD Victor E. Reuter, MD Memorial Sloan-Kettering Cancer Center reuterv@mskcc.org 66 th Annual Pathology Seminar California Society of Pathologists Short
More informationEpithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities
Pathology of Renal Neoplasia Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities Wael A Sakr, MD Wayne State University School of Medicine CURRENT CLASSIFICATION = EPITHELIAL
More informationImmunohistochemistry of clear cell tumours. What are clear cell tumours? Jan Klos 1
Immunohistochemistry of clear cell tumours J. Klos MD Department of Pathology Stavanger University Hospital Norway What are clear cell tumours? Multiple factors in etiology of clear cell changes: - technical
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK University College London, operating UK NEQS for ccredited to UK NEQS ICC & ISH
More informationThis module consists of four units which will provide the user a basic knowledge of cancer as a disease.
Module 5: What is Cancer? This module consists of four units which will provide the user a basic knowledge of cancer as a disease. After completing this module, cancer abstractors will be able to: Define
More informationApplications of immunohistology to non-heme tumor differential diagnosis R V Rouse 7/22/2014 http://surgpathcriteria.stanford.edu
Applications of immunohistology to non-heme tumor differential diagnosis R V Rouse 7/22/2014 http://surgpathcriteria.stanford.edu Table of Contents Page Undifferentiated panel 1 CK7/20 table 2 Breast carcinoma
More informationNEU IM PROGRAMM. LOXO Antikörper für die Immunhistochemie (alphabetisch nach Bezeichnung sortiert) Art.Code Artikelbezeichnung Typ Einsatz Einheit
A20002 Actin, Alpha-Smooth Muscle; Clone 1A4 monoklonal IHC 2 ml Ready-to-use A00002.0025 Actin, Alpha-Smooth Muscle; Clone 1A4 monoklonal IHC 25 ml Ready-to-use A00002 Actin, Alpha-Smooth Muscle; Clone
More informationNEOPLASMS C00 D49. Presented by Jan Halloran CCS
NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through
More informationCytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
More informationImmunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
Aus dem Institut für Pathologie der Medizinischen Fakultät Charité Universitätsmedizin Berlin DISSERTATION Immunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
More informationThe Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationFRCPath Part 2 Histopathology Short Cases, autumn 2014
FRCPath Part 2 Histopathology Short Cases, autumn 2014 Commentary Case 1 Female age 52: palpable lesion, left breast Breast, fat necrosis. Average: 2.6/5 This case was chosen as a good example of fat necrosis
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationMOC-31 Exhibits Superior Reactivity Compared With Ber-EP4 in Invasive Lobular and Ductal Carcinoma of the Breast. A Tissue Microarray Study
RESEARCH ARTICLE MOC-31 Exhibits Superior Reactivity Compared With Ber-EP4 in Invasive Lobular and Ductal Carcinoma of the Breast A Tissue Microarray Study Reetesh K. Pai, MD and Robert B. West, MD Abstract:
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationCytology of Effusion Fluids. Cytology of Effusion Fluids. Types of Effusion Fluids. Anatomy. Causes of Effusions. Sampling of Effusion Fluids
Cytology of Effusion Fluids John W. Wong, MD, FRCPC Sunnybrook Health Sciences Centre Assistant Professor, Laboratory Medicine and Pathobiology Faculty of Medicine, University of Toronto November 10, 2012
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationImmunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
More informationEmerging Subtypes in Renal Cancer. Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.
Emerging Subtypes in Renal Cancer Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.edu Some General Comments Fuhrman nuclear grading clear cell
More informationHow To Diagnose And Treat A Tumour In An Effusion
Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura
More informationmicrorna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH
More informationLung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine
Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationA Better Path for Cancer Diagnostics
INTERPRETATION FLEX Ready-to-Use Atlas of Stains - 4 th Edition A Better Path for Cancer Diagnostics Committed to raising the bar for higher quality During the last decades, organizations such as CAP,
More information3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
More informationDetermination of the type and origin of metastatic
Diagnosis of Metastatic Neoplasms An Immunohistochemical Approach Murli Krishna, MD N Context. It is important to determine the type and/or site of origin of metastatic tumors for optimal clinical management.
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationHow CanCer becomes critical in the claims
How CanCer becomes critical in the claims arena Cancer is a disease in which cells in your body grow in an uncontrolled way and form a lump called a tumour. In a healthy individual cells grow and reproduce
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationFrozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
More informationRENAL CELL CARCINOMA EPIDEMIOLOGY
RENAL CELL CARCINOMA: THE 2012 ISUP VANCOUVER CLASSIFICATION David Grignon MD, Indiana University, Indianapolis, IN RENAL CELL CARCINOMA EPIDEMIOLOGY Siegel et al. CaA Cancer J Clin 63:11-30, 2013 1 EPITHELIAL
More information- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa
- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological
More informationFNA Cytology of Mediastinal Lesions. Presenters: Xiaoqi Lin, M.D., Ph.D. Ritu Nayar, M.D.
Disclosure information The speakers have no relationship that represents a possible conflict of interest with respect to the content of this presentation. FNA Cytology of Mediastinal Lesions Presenters:
More informationAbstracts and References
Abstracts and References Soft Tissue Pathology Professor Cyril Fisher, Royal Marsden Hospital Learning points CD34 and CK positivity coexist in epithelioid sarcoma and epithelioid endothelial tumours.
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationDESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE
DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE Ryan Granger University of Rhode Island Cytotechnology program May 2, 2015 ASCT Annual Meeting Nashville, Tennessee DESMOPLASTIC SMALL ROUND
More informationImmunostain Update: Diagnosis of Metastatic Breast Carcinoma, Emphasizing the Distinction from Gynecologic Cancers
Immunostain Update: Diagnosis of Metastatic Breast Carcinoma, Emphasizing the Distinction from Gynecologic Cancers Yunn-Yi Chen, M.D., Ph.D. UCSF Pathology Department yunn-yi.chen@ucsf.edu June 3, 2010
More informationTFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY SYMBOL DEFINITIONS INTENDED USE PRINCIPLES AND PROCEDURES SUMMARY AND EXPLANATION
Rev. 0.0 TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY Cat. No. Description 354R-14 0.1 ml, concentrate 354R-15 0.5 ml, concentrate 354R-16 1.0 ml, concentrate 354R-17 1.0 ml, predilute
More information4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
More informationBAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationCASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY CASE HISTORY 52Y MALE RIGHT RADICAL NEPHERECTOMY Case of right renal mass with IVC thrombus. History of surgery and RT for right occipital
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationArticles. Nordic Immunohistochemical Quality Control (NordiQC) - An Organization for External Quality Assurance. Mogens Vyberg, MD
Articles Nordic Immunohistochemical Quality Control (NordiQC) - An Organization for External Quality Assurance Mogens Vyberg, MD Institute of Pathology. Aalborg Hospital Aarhus University Hospital Denmark
More informationHistory. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter.
FRCPath Part 2 Histopathology Examination Histology short cases Commentary. Case 1. History. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter. Diagnosis: Angiomyolipoma
More information20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationImmunohistochemistry (IHC) Outreach Services
Immunohistochemistry (IHC) Outreach Services Note t ype of fixative used if not neutral buffered f ormalin. Note t ype of tissue/specim en Unless specified otherwise, positive and negative controls react
More informationA Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma MICHAEL G. HURTUK and MICHELE CARBONE Cardinal Bernadin Cancer Center, Cancer Immunology Program, Department of Pathology,
More informationNeoplasms of the LUNG and PLEURA
Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationPleural and Pericardial fluids a one year analysis
Pleural and Pericardial fluids a one year analysis Dr Olafsdottir Dr J Williams Department of Cytology, Llandough Hospital Contents Background Standards Aims/Questions Investigation group Results Conclusions
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationDIFFICULTIES IN THE PATHOLOGIC DIAGNOSIS OF LUNG CANCER Notice of Financial Disclosures (TV Colby MD) (Esp. in small biopsies) Personal Experience Thomas V. Colby, M.D. Mayo Clinic Arizona NONE This talk
More information